
Opinion|Videos|January 27, 2025
Assessing Symptoms, Treatment Decision-Making, and Monitoring
Panelists discuss when to adjust the dosage of current therapies like sertraline vs considering alternative treatments and the factors that guide these decisions, as well as whether treatments with rapid onset, such as zuranolone capsules or brexanolone intravenous (IV) infusion, would be appropriate for cases like Sarah’s, and what factors would influence the choice between these options.
Advertisement
Episodes in this series

Advertisement
Related to this article

Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.

Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.

Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.

How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.

RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Evidence-Based Pharmacologic Approaches to Reducing Suicide Risk
2
Dissecting Algorithms of the Mind: Toward Precision Psychiatry in Schizophrenia
3
Fewer Than 1 in 5 Young Patients With First-Episode Psychosis Adhere to Antipsychotics
4
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
5


